Skip to main content
. 2020 May 29;15(5):e0233646. doi: 10.1371/journal.pone.0233646

Table 1. Baseline demographic and clinical characteristics.

Demographics Total group Low-group High-group P-value
N = 24 ≤ Median TAC dose > Median TAC dose
N = 12 N = 12
Age at HT (years) 55.8 ±2.3 55.2 ±3.6 56.3 ±3.2 0.82
Male (n, %) 21 (87.5) 10 (83.3) 11 (91.7) 1.0
Race 0.12
    White (n, %) 15 (62.5) 10 (83.3) 5 (41.7)
    Black (n, %) 7 (29) 2 (16.7) 5 (41.7)
    Other (n, %) 2(8) 0 2 (16.7)
BMI, Mean ± SE 25.9 ±0.9 27.7 ±1.5 24.1 ±0.7 0.05
Diabetes (n, %) 10 (41.7) 5 (41.7) 5 (41.7) 1.0
AFib (n, %) 13 (54.1) 8 (66.7) 5 (41.7) 0.41
Hyptertension (n, %) 17 (70.8) 8 (66.7) 9 (75) 1.0
LVAD prior to HT (n, %) 18 (75) 8 (66.7) 10 (83.3) 0.64
Time post-transplant (days) 63.5 ±5.9 65.1±8.2 61.8±8.8 0.79
Laboratory Values
Creatinine, mg/dL 1.34 ±0.11 1.32 ±0.17 1.37 ±0.14 0.74
AST, U/L 26.9 ±2.7 29.3 ±3.8 23.6 ±3.5 0.37
Total Bilirubin, mg/dL 0.56 ±0.11 0.48 ±0.11 0.66 ±0.22 0.35
Medications
Mycophenolate Mofetil (n, %) 20 (83.3) 8 (66.7) 12 (100) 0.09
Nystatin (n, %) 21 (87.5) 9 (75) 12 (100) 0.22
Valgancyclovir (n, %) 11 (45.8) 5 (41.7) 6 (50) 1.0
Trimethoprim/ sulfamethoxazole (n, %) 16 (66.7) 8 (66.7) 8 (66.7) 1.0
Dapsone (n, %) 7 (29.2) 2 (16.7) 5 (41.7) 0.37
Antibiotics (n, %)* 22 (91.6) 11 (91.6) 11 (91.6) 1.0
Aspirin (n, %) 20 (83.3) 10 (83.3) 10 (83.3) 1.0
Loop Diuretics (n, %) 12 (50) 6 (50) 6 (50) 1.0
Statins (n, %) 21 (87.5) 9 (75) 12 (100) 0.21
Proton Pump Inhibitors (n, %) 14 (58.3) 7 (58.3) 7 (58.3) 1.0

*Included only antibiotics for treatment

Values are presented as mean± standard error unless specified. T-Test or Chi-square/Fisher’s exact performed where appropriate. HT = heart transplant, LVAD = left ventricular assist device, BMI = body mass index, AST = aspartate aminotransferase, Afib = atrial fibrillation.